Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 0.75 |
| ▸ | TACR2 | P21452 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465985 | 0.88 | GNRHR (0.63) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4472894 | 0.87 | GNRHR (0.77) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3275214 | 0.86 | GNRHR (1.00) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4471830 | 0.86 | GNRHR (0.78) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4459787 | 0.83 | GNRHR (0.80) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4461442 | 0.81 | GNRHR (0.75) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4465228 | 0.79 | GNRHR (0.77) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3275062 | 0.77 | GNRHR (1.00) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4460786 | 0.77 | GNRHR (0.75) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4464100 | 0.76 | GNRHR (0.75) | GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538113-B2 | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2009-05-26 | — | — | US | claimed |
| US-20060189618-A1 | 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2006-08-24 | — | — | US | claimed |
| US-7538113-B2 | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2009-05-26 | — | — | US | disclosed |
| US-20060189618-A1 | 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189618-A1 | 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor | GNRHR, LHCGR, FSHR | GNRHR 1/4885TACR2 100/4885HRH2 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.